Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates

Journal of Infectious Diseases

Volumn 190, Issue 1, 2004, Pages 162-165

  Bangsberg, David R ^a   Porco, Travis C ^c   Kagay, C ^b   Charlebois, Edwin D ^a   Deeks, Steven G ^a   Guzman, David ^a   Clark, Richard ^a   Moss, Andrew ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c S Francisco Dept of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PATIENT COMPLIANCE;

EID: 3042842610     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/420790     Document Type: Article

References (15)

1. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-66.
2. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-3.
3. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-83.
4. Mayers DL. Drug-resistant HIV-1: the virus strikes back. JAMA 1998; 279:2000-2.
5. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999; 13(Suppl 1):S61-72.
6. Bangsberg D, Charlebois E, Grant R, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-32.
7. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA 2001; 286:196-207.
8. Walsh JC, Pozniak AL, Nelson MR, Mandalia S, Gazzard BG. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr 2002; 30:278-87.
9. Howard A, Arnsten J, Gardner L, et al. Lack of multi-drug resistance in nonresponders to antiretroviral therapy with poor adherence [abstract 604]. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires, 2001).
10. Gallego O, de Mendoza C, Perez-Elias MJ, et al. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS 2001; 15:1701-6.
11. Bangsberg D, Hecht F, Charlebois E, Chesney M, Moss A. Comparing objectives measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001; 5:275-81.
12. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002; 17:812-3.
13. King M, Brun S, Tschampa J, Moseley J, Kempf D. Exploring the effects of adherence on resistance: use of local linear regression to reveal relationships between adherence and resistance in antiretroviral-naive patients treated with lopinavir/ritonavir or nelfinavir. Antivir Ther 2003; 8:S108.
14. Miller L, McCutchan J, Keiser P, et al. Accumulation of antiretroviral resistance in treatment-experienced patients: the impact of medication adherence. Antivir Ther 2003; 8:S153.
15. Richman D, Bozzette S, Morton S, Wrin T, Dawson K, Hellman N. The prevalence of antiretroviral drug resistance in the US [abstract LB-17]. Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society of Microbiology, 2001.